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ABSTRACT
To reduce the risk of infection in adults and 
children with primary immunodeficiencies, 
replacement therapy with IgG, which can 
be administered to patients intravenously 
or subcutaneously, is required. Although 
intravenous administration of IgG (IVIG) has 
been the therapy of choice in the US and widely 
used in Europe for many years, subcutaneous 
administration of IgG (SCIG) has recently 
gained considerable acceptance among patients 
and doctors. SCIG therapy achieves high and 
stable serum IgG levels, is well tolerated, and 
can be self-administered. Hizentra® (IgPro20; 
CSL Behring, Berne, Switzerland) is the first, 
ready-to-use 20% liquid preparation of human 
IgG specifically formulated for subcutaneous 
infusions. The high concentration (20%) might 
allow shorter infusion times due to smaller 
infusion volumes, with potential improvement 
in the convenience of SCIG therapy. Hizentra 
is well tolerated and has been shown to protect 
adult and pediatric primary immunodeficiency 
patients against serious bacterial infections. In 
addition, it is easy to handle and can be stored at 
a temperature up to 25°C. In summary, Hizentra 
is an advance in the field of immunoglobulin 
replacement therapy, which might offer benefits 
for home therapy patients.
Keywords: Hizentra; subcutaneous IgG 
treatment; IgG; replacement therapy; primary 
immunodeficiency
INTRODUCTION
Patients with primary immunodeficiency 
(PI) disorders, such as common variable 
immunodef ic iency  (CVID) ,  X- l inked 
agammaglobulinemia (XLA), and autosomal 
recessive agammaglobulinemia (ARAG) that 
are caused by B-cell dysfunction are prone 
to recurrent bacterial infections.1,2 Lifelong 
immunoglobulin (Ig) replacement therapy is the 
only effective treatment for these patients, and 
is thus the gold standard in the management of 
primary antibody deficiency.3
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IgG can be administered subcutaneously 
(SCIG) or intravenously (IVIG) and was first used 
by Bruton in a child with agammaglobulinemia in 
1952.3 SCIG preparations were introduced in the 
1980s in the US and Europe. However, the slow 
infusion technique and the low concentration of 
the preparations available at the time made SCIG 
impractical and less attractive to patients and 
healthcare professionals. Therefore, IVIG, which 
allowed infusions of higher monthly doses, 
became the preferred route of administration. 
Despite its success, IVIG may not be suited to 
all patients, especially those with poor venous 
access. IVIG may be associated with systemic 
adverse events (AEs) and IVIG self-administration 
is technically more demanding and requires more 
training than SCIG self-administration. With 
recent technical advances in IgG formulation, 
pure and highly concentrated SCIG preparations 
that have relatively low viscosity, and can 
therefore be infused relatively rapidly, have 
been developed and are increasingly used 
worldwide.4-6 Usage of SCIG therapy varies greatly 
across countries and is predominant in Sweden, 
Germany, and the UK (Figure 1). 
While IVIG is infused every 3-4 weeks, SCIG is 
typically administered once a week, with the total 
IVIG monthly dose divided in smaller portions. 
The distribution of IgG between the vascular and 
extravascular compartments after subcutaneous 
administration can be described by a two-
compartment model, which accurately describes 
the distribution of serum IgG in healthy individuals 
and PI patients (Figure 2).7 In this model, IgG 
enters the vascular compartment (blood) from 
the extravascular compartment (subcutaneous 
space) via the lymphatics at a defined rate, which 
integrates IgG catabolism and total IgG distribution. 
This model predicts a progressive release of IgG into 
the circulation that contributes to the more stable 
serum IgG levels achieved with SCIG. 
Figure 1. Estimated market usage of intravenous 
administration of IgG (IVIG) versus subcutaneous 
administration of IgG (SCIG) for the treatment of primary 
immunodeficiencies. Estimated market usage of IVIG and 
SCIG is shown for selected European and North American 
countries (CSL Behring, unpublished results). *Local 
marketing affiliates estimate.
Figure 2. IgG distribution model. The serum IgG 
concentration depends on the rates of bidirectional 
movement across the endothelium, catabolism, and 
binding to targets. The IgG catabolism is mediated by 
the neonatal Fc receptor (FcRn), with FcRn-bound IgG 
molecules being salvaged from degradation and returned to 
the circulation. IVIG=intravenous administration of IgG; 
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In comparison to IVIG, SCIG results in more 
sustained serum IgG levels, avoiding the peaks 
and troughs associated with IVIG.6,8 SCIG is 
associated with fewer systemic AEs than IVIG 
and requires no venous access.4,6,8 Finally, SCIG 
is easy to use and is easier to self-administer, 
providing patients with flexibility and improved 
quality of life.9 Patients treated with SCIG do not 
need to go to the hospital or infusion centers, 
avoiding unnecessary travel and their potential 
concerns for acquiring nosocomial infections. 
Patients require less assistance from healthcare 
professionals, reducing the cost associated with Ig 
replacement therapy, and can take greater control 
over their therapy. This review summarizes the 
available data on and practical considerations 
regarding the use of the subcutaneous 20% 
IgG preparation, IgPro20 (CSL Behring, Berne, 
Switzerland), currently marketed in the US under 
the brand name of Hizentra®. Hizentra has a good 
safety profile and has been shown to effectively 
protect PI patients from serious and non-serious 
bacterial infections.10,11
INTRODUCING HIZENTRA
Hizentra is a 20% (200 g/L) ready-to-use 
liquid preparation of polyvalent human IgG 
for subcutaneous administration that is well 
tolerated.10,11 Currently, it is the only 20% SCIG 
therapy approved by the US Food and Drug 
Administration (FDA) for the treatment of PIs. 
The safety, tolerability, and efficacy of Hizentra 
have been tested in phase 1 and 3 clinical trials 
involving a total of 48 healthy subjects10,12 and 
100 patients.10,11
Formulation
Hizentra has high purity (≥98% IgG and only 
trace amounts of IgA; Table 1) and is formulated 
without preservatives.13 In contrast to other 
subcutaneous IgG preparations, it is stabilized with 
l-proline (250 mmol/L), a nonessential natural 
amino acid found at high level in human plasma. 
The amphiphilic property of l-proline prevents the 
dimerization and/or aggregation of IgG molecules 
in the concentrated solution during storage. 
In addition, the presence of l-proline enables 
the final formulation to have a low viscosity 
(14.7±1.2 mPa/second), which is comparable to 
that of other SCIG formulations (eg, the 16% SCIG 
Vivaglobin®; CSL Behring, Marburg, Germany; 
14.4 mPa/second) and compatible with the 
infusion pumps in current use.13,14
Manufacture
Hizentra is manufactured from human plasma 
derived from usually more than 6000 donors by 
a multistep process identical to that of IgPro10 
Characteristic Parameter
Protein concentration 200 g/L
IgG content ≥98%
IgA content ≤50 µg/mL
L-proline 210-290 mmol/L




Stability Stable at room temperature (up 
to 25°C) for up to 24 months





15 mL for the first four 




15 mL/hour/site for the first 
infusion; maximum 25 mL/hour/
site for following infusions
IgA=immunoglobulin A; IgG=immunoglobulin G.
Table 1. Hizentra characteristics.
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production (Privigen®; CSL Behring, Berne, 
Switzerland). The process includes cold ethanol 
fractionation, octanoic acid precipitation, and 
anion-exchange chromatography.15 In order to 
minimize potential inadvertent transmission 
of blood-transmitted viruses, collected 
plasma donations are screened for hepatitis B, 
hepatitis C, human immunodeficiency virus, 
and B19 virus. Only donations with negative 
test results are used for production.15 The 
manufacturing process includes steps that 
are specifically designed to remove/inactivate 
viruses over and above viral screening 
undertaken on all donated plasma. These 
steps are virus inactivation by incubation 
at pH 4, virus reduction by partitioning 
mechanisms, and virus (nano)filtration.15 The 
process has been shown to have the potential 
for an overall reduction in known viruses 
ranging from >107 to >1024, depending on the 
model virus tested.15 By combining thorough 
virus screening of donations with rigorous 
manufacturing processes, the likelihood of 
blood-borne virus transmission is reduced 
to a minimum. Similarly, the manufacturing 
process has been shown to have a very 
high potential for reduction of prions, the 
transmissible spongiform encephalopathy 
agents, ranging from >1010 to >1014.15 Taken 
together, this results in a state-of-the-art 
product with respect to pathogen safety.15
Profiling of product-related and process-
related impurities includes the procoagulatory 
factors, factor IX and factor XIa. Testing has 
shown that these factors are present in the 
starting material, but are depleted below assay 
detection levels by octanoic acid fractionation. 
As a consequence, these factors are undetectable 
in the final product, minimizing their potential 
contribution to the risk of thromboembolic 
events. Current post-marketing safety data 
for Privigen indicate a very low incidence 
of thromboembolic events (CSL Behring, 
unpublished results). Identical post-marketing 
safety monitoring is in place for Hizentra. 
Currently, testing of procoagulatory factors 
or activities in IVIG/SCIG products is not a 
regulatory requirement for product release. 
However, discussions are ongoing between 
industry and regulatory authorities (FDA, 
European Medicines Agency) on the possible use 
of functional assays for routine measurement of 
thrombogenic (procoagulant) activity in IVIG/
SCIG products. Such assays test the ability of a 
given entity to activate the intrinsic or extrinsic 
pathways of coagulation.
Stability
The stability of Hizentra has been tested after 24 
months of storage in the dark at 5°C, 25°C, and 
30°C, with regards to protein integrity, antigen-
specific antibody titers, and Fc function, 
according to International Conference on 
Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human 
Use (ICH) guidelines.16 Storage at up to 25°C 
for 24 months showed values within predefined 
specifications.13 In highly concentrated IgG 
solutions, proteins tend to aggregate and 
fragment, which may result in reduced efficacy 
and poor tolerability. After 24 months of storage 
at up to 25°C, the content of aggregates in 
Hizentra increased from approximately <0.1% 
to ≤0.5% (specification: ≤4%) and the content of 
monomers/dimers changed from approximately 
98% to approximately 95% (specification: 
≥90%).13 The content of fragments was ≤4%, 
which is below the specified limits of ≤10%.13
Furthermore, long-term storage did not 
significantly affect antigen-specific antibody 
titers (eg, anti-hepatitis B, anti-streptolysin O, 
anti-measles, anti-polio type 1, anti-parvovirus 
B19, and diphtheria antitoxin), which remained 
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above or significantly exceeded specified 
levels.13 Finally, after 24 months of storage 
at up to 25°C, the Fc function changed from 
approximately 100% to between 79% and 101% 
in Fc-receptor-mediated leukocyte activation 
assays, including assays of complement and 
neutrophil activation. The Fc function was 
therefore maintained above the specified 
limit of 60% upon long-term storage at up to 
25°C. An extension of Hizentra shelf life to 
30 months at up to 25°C was recently approved 
by the FDA.17 These long-term storage qualities 
simplify product storage in pharmacies, at 
home, or during travel. In addition, as delivery 
can take place less frequently and a dedicated 
fridge is no longer needed, the cost of home 
delivery packages may decrease.
Indications and Additional Treatment 
Options for Patients
Hizentra is registered in the US, and pending 
approval in Europe and other countries, for 
treatment of PIs, which include but are not 
limited to congenital agammaglobulinemia, 
CVID, XLA, Wiskott-Aldrich syndrome, and 
severe combined immunodeficiencies.18 It is 
also labeled for secondary immunodeficiencies 
in countries outside the US. SCIG is often 
administered only during the maintenance 
phase of immunoglobulin replacement therapy, 
while IVIG is administered during both the 
initiation and the maintenance phase. A recent 
study of Vivaglobin showed that initiation of 
immunoglobulin replacement treatment with 
SCIG therapy successfully achieved sufficiently 
high IgG trough levels (≥5 g/L) and was well 
tolerated (Borte et al., unpublished results). 
Although practice varies across countries, the 
usage of SCIG from the very beginning of 
replacement therapy, including the loading 
phase, is increasingly being used in Europe. 
Beside immunodeficiencies, IVIG therapy 
shows efficacy in the treatment of myopathies 
and autoimmune neurological conditions, 
especially multifocal motor neuropathy, chronic 
inflammatory demyelinating polyneuropathy, 
and Guillain-Barré syndrome.19 Although there 
are limited data on the use of SCIG for immune 
modulation, SCIG was recently successfully 
used in maintenance therapy of multifocal 
motor neuropathy 20-23 and in the treatment of 
polymyositis and dermatomyositis.24 The range 
of therapeutic areas in which SCIG could be 
applied successfully during the maintenance 
phase is therefore expanding beyond immune 
replacement therapy for primary antibody 
deficiency into immunomodulation. However, 
it remains to be elucidated whether the 
high peaks of IgG levels following IVIG 
infusions are required to achieve remission in 
these diseases. 
Efficacy
Two prospective, open-label, multicenter, single-
arm, phase 3 clinical trials, one performed in the 
US and one in Europe, evaluated the efficacy and 
safety of Hizentra in patients with PI over 60 and 
40 weeks, respectively. 
In the US clinical trial, 49 CVID or XLA 
patients, who were previously successfully 
treated with monthly IVIG infusions, were 
switched to weekly SCIG self-infusions.10 The 
trial consisted of a 12-week wash-in/wash-
out period, followed by a 48-week efficacy 
period. At the beginning of the efficacy period, 
doses were adjusted individually to 1.53 times 
the IVIG dose to achieve areas under the 
concentration-time curves (AUCs) for serum 
IgG that were comparable to the AUCs obtained 
with previous IVIG treatment, in line with FDA 
requirements. The dose adjustment coefficient 
of 1.53 had been specifically determined 
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for Hizentra in a pharmacokinetic substudy 
included in this trial.25
In the European trial, 51 PI patients 
previously on stable IVIG or SCIG therapy 
switched to weekly self-administration of 
Hizentra at monthly doses equivalent to their 
previous treatment. A 12-week wash-in/wash-out 
period was followed by a 28-week efficacy period 
completed by 43 patients, including 16 patients 
below the age of 12 years. A pharmacokinetic 
substudy was conducted in 18 patients to 
determine the variation in steady-state serum 
IgG concentrations between infusions.
Weekly subcutaneous administration of Hizentra 
to PI patients resulted in serum IgG levels within 
the normal range. The mean IgG trough levels 
during the efficacy period of the two clinical trials 
were within the range found in healthy individuals 
(mean level: 12.5 g/L in the US study and 8.1 g/L 
in the European study).10,11,26,27 In addition, the 
pharmacokinetic substudy of the European trial 
showed that serum IgG levels remained stable 
between SCIG infusions (Figure 3).11
In keeping with the high and sustained 
serum IgG levels, no serious bacterial infections 
(SBIs) occurred during the efficacy period of 
the two studies.10,11 One pediatric patient in 
the European study experienced pneumonia, 
qualified as an SBI, during the wash-in/wash-
out period, on a background of historical 
recurrent pulmonary infections.11 The rate of 
any infections was 2.76 events/patient/year in 
the US trial and 5.18 events/patient/year in the 
European trial (Figure 4).10,11 Consistent with 
the low incidence of infections, the rate of days 
missed from work/school was 2.06 days/patient/
year and 8.00 days/patient/year in the US and 
European trials, respectively, and the rate of 
days spent in hospital was 0.2 days/patient/year 
and 3.48 days/patient/year, respectively.10,11
Direct comparison of these results is not 
possible because the studies were not powered 
to determine dose-related differences in clinical 
outcomes. Moreover, a number of factors, 
such as country-specific medical practices for 
diagnosing infections, cultural differences 
relating to absence from work/school, and the 
higher number of children in the European Figure 3. Serum IgG concentrations during one Hizentra 
dosing interval in the European trial. Mean and standard 
error of the serum IgG concentrations measured during  
1 week are shown. Samples were collected up to 30 
minutes before the start of the infusion (preinfusion),  
10 minutes prior to the end of the infusion (10 minutes), 
2 hours after the end of the infusion (2 hours), and after 
1, 2, 3, 4, and 7 days.11
Figure 4. Rates of infections in primary immunodeficiency 
patients treated with Hizentra. The rates of any infections 
reported in the US trial10 and in the European trial11 are 
shown. No serious bacterial infections occurred during the 
efficacy period of either trial.
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Second, patients may not need to wait for the 
solution to warm up before infusion, reducing 
the overall duration of an infusion. Finally, with 
its high stability at 25°C, Hizentra could easily 
be transported, increasing flexibility for patients 
when they travel. 
Reduced Infusion Duration
The high IgG content (200 g/L) and relatively low 
viscosity influence the volume and duration of 
infusion.13 Currently, 16% IgG preparations, such 
as Vivaglobin, are infused at 10-20 mL per hour.6,8
Hizentra was infused at a median infusion rate of 
25.3 mL/hour in the recent European study, and 
rates as high as 35.0 mL/hour were used in 34.8% 
of patients.11 In the US study, the median infusion 
rate was 39.1 mL/hour, with a maximum infusion 
rate of 50 mL/hour for all simultaneously used 
sites.10 The high infusion rates, as well as the small 
volume required, led to a short duration of weekly 
infusions, with median values ranging from 1.14 
to 1.27 hours11 and from 1.6 to 2 hours.10
Benefits for Pediatric Patients
SCIG therapy is particularly attractive for 
pediatric patients because it does not require 
venous access and because it is relatively free 
of systemic AEs. It was previously shown that 
a young infant with XLA was successfully 
switched from IVIG to SCIG with no SCIG-
related AEs reported.28 Pediatric patients have 
been treated successfully with SCIG in several 
studies.29-32 Hizentra may be especially well 
suited to pediatric patients because the 20% 
concentration allows the delivery of the required 
dose in a smaller volume. The efficacy and 
safety of Hizentra in 23 pediatric patients was 
assessed in the European phase 3 clinical trial 
(Borte et al., unpublished results). A total of 
21 pediatric patients, including 16 children 
study may have contributed to the differences in 
efficacy results obtained. Despite differences in 
the two clinical trials, both studies demonstrated 
that Hizentra achieved clinical efficacy in 
patients with PI, with stable and physiologically 
relevant serum IgG levels.
Safety
Hizentra is well tolerated by PI patients.10,11 Most 
AEs reported in both phase 3 clinical trials were of 
mild or moderate intensity.10,11 As expected with 
subcutaneous infusions, the most common AEs 
were local injection site reactions, with rates of 
0.580 events/infusion and 0.060 events/infusion 
in the US and European trials, respectively.10,11
Patients’ tolerability to local reactions improved 
over time. Systemic AEs, such as headache, 
fatigue, and nausea were relatively rare. For 
example, the rate of headache was 0.018 events/
infusion in the US trial and 0.029 events/infusion 
in the European trial. No serious AEs were 
considered related to Hizentra treatment.
CONSIDERATIONS FOR USING 
HIZENTRA
Hizentra introduces a number of important 
potential benefits to IgG replacement therapy. 
Several of these are described below. 
Convenient Storage at Room Temperature
Hizentra can be stored at up to 25°C for up to 
30 months without compromising its safety and 
biological activity, bringing a number of benefits 
to patients and healthcare professionals.13 First, 
the need to maintain refrigeration facilities 
at hospitals or doctor’s offices is obviated for 
many countries, and storage at home is easier 
for patients, especially when several months 
worth of immunoglobulin is delivered at once. 
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(age, 2-11 years) and five adolescents (age, 12-15 
years), completed the efficacy period of this trial. 
As four out of five adolescents were previously 
treated with SCIG, the mean serum IgG trough 
level achieved in adolescents was comparable to 
that at study start (from 7.99 g/L to 7.91 g/L) 
(Borte et al., unpublished results). In contrast, 
with two-thirds of the children previously 
treated with IVIG, the mean IgG trough level 
increased by 13.3% (from 6.94 g/L to 7.86 g/L) 
in children (Borte et al., unpublished results). No 
SBI occurred during the efficacy period. 
Low rates of local injection site reactions were 
observed in children (0.040 events/infusion) and 
adolescents (0.035 events/infusion) (Borte et al., 
unpublished results). In addition, excluding 
local reactions, the rate of AEs was lower in 
children (0.158 events/infusion) and adolescents 
(0.206 events/infusion) than in adults (0.282 
events/infusion). Treatment of pediatric patients 
with Hizentra was well tolerated and effective 
in protecting them from infections without any 
specific dose adjustment of the previous IVIG 
dose (Borte et al., unpublished results).
Health-Related Quality of Life (HRQL) and 
Self-administration
The poor HRQL of untreated patients with PI 
was markedly improved by SCIG therapy,33 
and further improved by home therapy with 
SCIG.4,9 Home therapy allows patients to have 
more control over their treatment, giving them 
a sense of responsibility and independence. 
In addition, patients have the choice to 
schedule their infusions at a time that is most 
convenient for them, limiting the disruption 
of their daily activities.
The impact of Hizentra on HRQL of PI 
patients was investigated in the European phase 
3 clinical trial.11 The patients enrolled in this trial 
had been previously treated with either IVIG 
(29 patients) or SCIG (19 patients) and switched 
to weekly doses of Hizentra. At baseline, the 
HRQL, as assessed by the Life Quality Index 
and Treatment Satisfactory Questionnaire for 
Medication, was better in patients previously 
on SCIG than in those previously on IVIG. After 
switching to Hizentra, the HRQL remained 
stable for the former and improved for the 
latter, with a statistically significant change in 
median Treatment Satisfactory Questionnaire for 
Medication domain score for “convenience” (from 
55.6 at baseline to 83.3 at study end; 95% CI: 22.2, 
38.9). These results support previous data on the 
positive impact of SCIG therapy on HRQL in PI 
patients, when compared to IVIG therapy.34-37 This 
is also reflected in the clinical practice in Cardiff, 
UK, where more than 80% of new PI patients 
choose SCIG over IVIG (unpublished data). The 
impact of Hizentra on HRQL compared to other 
SCIG therapies is currently being investigated in 
greater detail in patients treated with SCIG and 
transitioning to Hizentra.
Equipment Required for Hizentra Infusion
SCIG preparations can be infused with 
conventional infusion pumps, such as Crono 
Super-PID infusion, FREEDOM60 Syringe 
Infusion System (Repro-Med Systems, Inc., NY, 
USA), Micrel Micropump MP™ (Micrel Medical 
Devices S.A., Athens, Greece), or Cane Crono 
PCA-50 (Figure 5). In the European trial, Cane 
Crono PCA-50 or Super-PID infusion pumps 
(Cane S.R.L., Turin, Italy) were used to infuse 
Hizentra, while, in the US trial, Cane Crono 
PCA-50 pumps were used. In the clinical practice 
at Cardiff, UK, Crono pumps have become the 
standard for new patients commencing SCIG 
infusions, and are specified with the home care 
packages provided. In the US, the FREEDOM60 
Syringe Infusion System is most often used. This 
system is simple, reliable, and does not depend 
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on batteries or electrical outlets. Infusions are 
given through a 91.4-cm (36-inch) bifurcated 
tubing system with a 27-gauge needle that is 
6, 9, or 12 mm in length. A common cause of 
site-associated AEs with SCIG is using shorter, 
6 mm needles in adults leading to intradermal 
rather than subcutaneous infusion. 
An emerging alternative to conventional 
pump-assisted SCIG infusion is the frequent 
push technique with one to seven infusions 
per week. This technique consists of the more 
frequent manual infusion of small portions of 
the weekly dose using a syringe and a 23-25-
gauge butterfly needle. A recent retrospective 
analysis in PI patients treated with Vivaglobin 
showed that, if the same weekly dose is used, 
both techniques are equivalent in terms of serum 
IgG levels and safety.38 As no pump or tubing is 
required with the frequent push technique, the 
cost and time for equipment maintenance are 
considerably reduced, making this approach 
attractive to patients and insurance companies. 
Training for Self-administration of Hizentra
At the beginning of the two phase 3 clinical 
trials, training sessions were conducted at the 
study sites to teach patients how to self-infuse 
and to teach parents of pediatric patients 
how to perform SCIG infusions on their child. 
Figure 5. Pumps for subcutaneous administration of IgG (SCIG) infusions and SCIG infusion. (A) Crono Super-PID 
infusion. (B) FREEDOM60 Syringe Infusion System. (C) Micrel Micropump MP. (D) Photo of subcutaneous infusion with 
a Cane Crono PCA-50 pump. Reproduced with the kind permission of OMT GmbH & Co. KG.
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Self-infusion was not reported as being difficult 
and no patients were discontinued from either 
trial because of technical difficulties.10,11 As with 
other SCIG products, self-infusion with Hizentra 
was shown to be easy to learn. In clinical practice, 
the duration and modalities of training programs 
for SCIG self-infusion may vary from country to 
country. In Cardiff, UK, the training, supervised 
by healthcare personnel, consists of six infusions 
at the day care unit of the University Hospital of 
Wales, with the procedures being increasingly 
managed by the patient. The nursing team 
then visits the patient at home for their first 
independent home infusion and ensures that 
the patient is confident with the procedure. In 
the US, the training takes place at the doctor’s 
office or at the patient’s home with the help of 
nurses skilled in SCIG administration. During 
the training sessions, the selection of proper 
subcutaneous needle gauge and length, the 
selection of infusion sites, the management 
of local adverse reactions, and the use of the 
infusion equipment including aseptic infusion 
skills and proper disposal of infusion materials are 
reviewed. Generally, patients can independently 
self-infuse SCIG doses after three to four training 
sessions, and a protocol to initiate and monitor 
patients with Hizentra is proposed (Figure 6). For 
previously untreated patients, the initial loading 
phase of five daily subcutaneous infusions of 
100 mg/kg affords the opportunity to rapidly 
train patients for subsequent home therapy. 
During the maintenance phase, patients self-
administer their SCIG dose at home each week. 
Monitoring and management of the disease and 
treatment would occur at a frequency appropriate 
for each patient (Figure 6).
Doses 
For the treatment of PIs, dose adjustment 
when switching from IVIG to SCIG therapy 
is still a matter of debate. In the European 
Hizentra study, doses equivalent to previous 
IVIG doses were administered according to the 
clinical practice in Europe.11 In contrast, the US 
Hizentra study aimed to achieve AUCs similar 
to that of previous IVIG treatment.10 Therefore, 
Figure 6. Proposed model for treatment of primary immunodeficiency patients with Hizentra. Infusions occur daily during 
the initiation phase and weekly during the maintenance phase. The training program may vary in length from country to 
country and will include training on pump use. 
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in this trial, Hizentra doses were adjusted at 
the beginning of the efficacy period either 
individually or using a mean dose adjustment 
coefficient of 1.53, and thus the resulting doses 
were 1.49 times higher than the doses during 
previous IVIG therapy.25
The European study showed that using doses 
equivalent to previous IVIG doses resulted in a 
17.7% increase in serum IgG levels in patients 
switching from IVIG to SCIG, and protected 
patients from SBIs, suggesting that a dose 
adjustment coefficient of 1.53 is not required.11
While stable serum IgG levels, in the 
physiological range of immunocompetent 
individuals, were achieved in both studies, 
these studies alone were not powered to 
answer the independent question regarding 
the level of serum IgG required to provide 
optimal protection from infections overall.10,11
However, published data on immunoglobulin 
replacement therapy, including the two 
Hizentra clinical trials, support a linear 
correlation between serum IgG trough level 
and infection rate, with higher trough levels 
associated with fewer infections.6,8,10,11,25,39,40
While there is increasing evidence for 
improvements in outcomes associated with 
increasing trough levels up to a level of 10 g/L, 
it is important to base the optimization of dose 
on the overall clinical assessment of individual 
patients rather than the steady state IgG level 
alone.10,11,40 Clinical indicators of efficacy include 
the frequency of sinopulmonary infections, the 
frequency and duration of antibiotic therapy, 
and the overall well-being of the patient.
Prevalence and Management of AEs 
Associated with SCIG
In comparison to IVIG therapy, a major 
advantage of SCIG therapy is the very low 
frequency of systemic AEs, such as headaches, 
nausea, and fatigue.6,8,10,41 Most systemic AEs 
following IVIG occur during the infusion or 
within 48 hours post infusion, when the serum 
IgG level is increasing or near its peak. With 
less variable serum IgG levels, SCIG therapy is 
relatively free of systemic AEs. All systemic AEs 
related to Hizentra administration were mild or 
moderate in intensity.10,11
Local injection site reactions, typically 
associated with SCIG therapy, may include edema, 
erythema, and itching, which, if treatment is 
required, can usually be managed easily with 
antihistamines and analgesics. These local AEs are 
generally mild and transient, and mainly require 
no intervention. In addition, the proportion of 
patients experiencing AEs tends to decline over 
time, as patients become accustomed to the 
product and procedure.6,10,41 Most local reactions 
after Hizentra administration were also mild and 
showed a decreasing frequency over time.10
Overall, Hizentra is well tolerated by 
patients, with regards to both local and 
systemic reactions, making this product ideal for 
self-administration. 
CONCLUSION
Clinical research and clinical practice have 
shown that SCIG therapy is effective and 
well tolerated in patients with PI. With its 
short infusion duration and stability at up to 
25°C, Hizentra, a new 20% SCIG preparation, 
represents a further advance in the field of SCIG 
therapy for patients with PI, including pediatric 
patients and frequent travelers.
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